AU2012345975B2 - Anticoagulant reversal agents - Google Patents

Anticoagulant reversal agents Download PDF

Info

Publication number
AU2012345975B2
AU2012345975B2 AU2012345975A AU2012345975A AU2012345975B2 AU 2012345975 B2 AU2012345975 B2 AU 2012345975B2 AU 2012345975 A AU2012345975 A AU 2012345975A AU 2012345975 A AU2012345975 A AU 2012345975A AU 2012345975 B2 AU2012345975 B2 AU 2012345975B2
Authority
AU
Australia
Prior art keywords
compound
dap
subject
pharmaceutically acceptable
anticoagulant
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2012345975A
Other languages
English (en)
Other versions
AU2012345975A1 (en
Inventor
Sasha H. Bakhru
Bryan E. Laulicht
Edith Mathiowitz
Solomon S. Steiner
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Covis Pharma GmbH
Original Assignee
Covis Pharma GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47430065&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AU2012345975(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Covis Pharma GmbH filed Critical Covis Pharma GmbH
Publication of AU2012345975A1 publication Critical patent/AU2012345975A1/en
Application granted granted Critical
Publication of AU2012345975B2 publication Critical patent/AU2012345975B2/en
Assigned to PEROSPHERE PHARMACEUTICALS INC. reassignment PEROSPHERE PHARMACEUTICALS INC. Request to Amend Deed and Register Assignors: PEROSPHERE INC.
Assigned to COVIS PHARMA GMBH reassignment COVIS PHARMA GMBH Request for Assignment Assignors: PEROSPHERE PHARMACEUTICALS INC.
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/04—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
    • C07D295/125—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • C07D295/13—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Vascular Medicine (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AU2012345975A 2011-11-29 2012-11-29 Anticoagulant reversal agents Active AU2012345975B2 (en)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US201161564559P 2011-11-29 2011-11-29
US61/564,559 2011-11-29
US201261614292P 2012-03-22 2012-03-22
US61/614,292 2012-03-22
US201261641698P 2012-05-02 2012-05-02
US61/641,698 2012-05-02
US201261666291P 2012-06-29 2012-06-29
US61/666,291 2012-06-29
PCT/US2012/066938 WO2013082210A1 (en) 2011-11-29 2012-11-29 Anticoagulant reversal agents

Publications (2)

Publication Number Publication Date
AU2012345975A1 AU2012345975A1 (en) 2014-05-29
AU2012345975B2 true AU2012345975B2 (en) 2016-12-15

Family

ID=47430065

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2012345975A Active AU2012345975B2 (en) 2011-11-29 2012-11-29 Anticoagulant reversal agents

Country Status (34)

Country Link
US (5) US9522892B2 (cg-RX-API-DMAC7.html)
EP (1) EP2785700B1 (cg-RX-API-DMAC7.html)
JP (1) JP6134731B2 (cg-RX-API-DMAC7.html)
KR (1) KR101892330B1 (cg-RX-API-DMAC7.html)
CN (1) CN104080772B (cg-RX-API-DMAC7.html)
AP (1) AP2014007662A0 (cg-RX-API-DMAC7.html)
AR (1) AR089020A1 (cg-RX-API-DMAC7.html)
AU (1) AU2012345975B2 (cg-RX-API-DMAC7.html)
BR (1) BR112014012892B1 (cg-RX-API-DMAC7.html)
CA (1) CA2856540C (cg-RX-API-DMAC7.html)
CL (1) CL2014001399A1 (cg-RX-API-DMAC7.html)
CO (1) CO6990738A2 (cg-RX-API-DMAC7.html)
CR (1) CR20140310A (cg-RX-API-DMAC7.html)
CY (1) CY1117414T1 (cg-RX-API-DMAC7.html)
DK (1) DK2785700T3 (cg-RX-API-DMAC7.html)
EA (1) EA027603B1 (cg-RX-API-DMAC7.html)
EC (1) ECSP14006696A (cg-RX-API-DMAC7.html)
ES (1) ES2569674T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20160513T1 (cg-RX-API-DMAC7.html)
HU (1) HUE027452T2 (cg-RX-API-DMAC7.html)
IL (1) IL232788B (cg-RX-API-DMAC7.html)
ME (1) ME02424B (cg-RX-API-DMAC7.html)
MX (1) MX349514B (cg-RX-API-DMAC7.html)
PE (1) PE20141295A1 (cg-RX-API-DMAC7.html)
PH (1) PH12014501176B1 (cg-RX-API-DMAC7.html)
PL (1) PL2785700T3 (cg-RX-API-DMAC7.html)
PT (1) PT2785700E (cg-RX-API-DMAC7.html)
RS (1) RS54738B1 (cg-RX-API-DMAC7.html)
SG (1) SG11201402713WA (cg-RX-API-DMAC7.html)
SI (1) SI2785700T1 (cg-RX-API-DMAC7.html)
SM (1) SMT201600161B (cg-RX-API-DMAC7.html)
UA (1) UA116336C2 (cg-RX-API-DMAC7.html)
WO (1) WO2013082210A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201404793B (cg-RX-API-DMAC7.html)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015069844A1 (en) * 2013-11-08 2015-05-14 Perosphere Inc. Labeled compounds and methods of imaging, diagnosing cartilage disorders and diseases, and monitoring cartilage health using labeled and unlabeled compounds
TWI828027B (zh) 2016-03-28 2024-01-01 美商英塞特公司 作為tam抑制劑之吡咯并三嗪化合物
US10633387B2 (en) 2017-09-27 2020-04-28 Incyte Corporation Salts of TAM inhibitors
PE20200719A1 (es) * 2017-11-13 2020-07-21 Maximum Fidelity Surgical Simulations Llc Reconstitucion de la circulacion posmortem, metodos y procedimientos especializados
ES3031110T3 (en) 2018-06-29 2025-07-04 Incyte Corp Formulations of an axl/mer inhibitor
US11716989B2 (en) 2019-04-16 2023-08-08 Maximum Fidelity Surgical Simulations, LLC Cadaver preservation systems and methods
US11915610B2 (en) 2019-05-15 2024-02-27 Maximum Fidelity Surgical Simulations, LLC Cadaverous heart model
CN112010930B (zh) * 2019-05-28 2022-08-02 首都医科大学 Rgd修饰的五环哌嗪二酮及其制备和应用
PH12022552347A1 (en) 2020-03-06 2024-01-29 Incyte Corp Combination therapy comprising axl/mer and pd-1/pd-l1 inhibitors
EP4692086A1 (en) 2023-03-24 2026-02-11 Shaanxi Micot Pharmaceutical Technology Co., Ltd. Anticoagulation reversal agent, and preparation method therefor and use thereof
CN117624137A (zh) * 2023-12-04 2024-03-01 中国药科大学 三嗪骨架小分子肝素逆转剂及其制备方法与用途
US20250389737A1 (en) * 2024-06-20 2025-12-25 Instrumentation Laboratory Company FACTOR Xa REAGENT
EP4667582A1 (en) * 2024-06-20 2025-12-24 Instrumentation Laboratory Company Factor xa reagent
CN121622691A (zh) * 2024-08-30 2026-03-10 陕西麦科奥特医药科技股份有限公司 使用抗凝逆转剂治疗抗凝剂导致的出血的方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3678157A (en) * 1968-10-23 1972-07-18 Oreal Hair treatment compositions containing polycondensable compounds

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL115420A0 (en) * 1994-09-26 1995-12-31 Zeneca Ltd Aminoheterocyclic derivatives
US6069232A (en) * 1995-10-02 2000-05-30 Hoechst Marion Roussel, Inc. Polyfluoroalkyl tryptophan tripeptide thrombin inhibitors
US6080852A (en) 1996-06-27 2000-06-27 The Perkin-Elmer Corporation 4,7-dichlororhodamine dyes
CA2268381A1 (en) 1996-10-11 1998-04-23 Cor Therapeutics, Inc. Selective factor xa inhibitors
CA2285454A1 (en) * 1997-04-07 1998-10-15 Axys Pharmaceuticals Corporation Compounds and compositions for treating diseases associated with serine protease, particularly tryptase, activity
FR2781221B1 (fr) * 1998-07-17 2000-10-13 Lafon Labor Piperazinones substituees en alpha
WO2000038683A1 (en) * 1998-12-23 2000-07-06 Du Pont Pharmaceuticals Company THROMBIN OR FACTOR Xa INHIBITORS
JP2002544263A (ja) 1999-05-19 2002-12-24 ファルマシア・コーポレイション 抗凝血剤としての置換多環式アリールおよびヘテロアリールウラシル
CA2412345A1 (en) 1999-06-16 2000-12-21 University Of Iowa Research Foundation Antagonism of immunostimulatory cpg-oligonucleotides by 4-aminoquinolines and other weak bases
EP1274676A2 (en) 2000-04-17 2003-01-15 Pharmacia Corporation Polycyclic aryl and heteroaryl substituted 1,4-quinones useful for selective inhibition of the coagulation cascade
US6586418B2 (en) * 2000-06-29 2003-07-01 Bristol-Myers Squibb Company Thrombin or factor Xa inhibitors
BR0213092A (pt) 2001-10-03 2004-10-19 Pharmacia Corp Compostos heterocìclicos de 6 elementos úteis para a inibição seletiva da cascata de coagulação
WO2003082809A1 (en) * 2002-03-27 2003-10-09 Glaxo Group Limited Diaminoacid-aminoacid-polyamine based gemini surfactant compounds
JPWO2003099324A1 (ja) * 2002-05-23 2005-09-22 中外製薬株式会社 組織因子阻害剤中和剤及び活性型血液凝固第ｖｉｉ因子製剤中和剤
GB0214122D0 (en) 2002-06-19 2002-07-31 Eastman Kodak Co High contrast photographic element containing a polyhydrazide nucleating agent
SE0400014D0 (sv) * 2004-01-08 2004-01-08 Astrazeneca Ab Heterocyclic derivatives
US20060045865A1 (en) 2004-08-27 2006-03-02 Spherics, Inc. Controlled regional oral delivery
JPWO2008105441A1 (ja) * 2007-02-27 2010-06-03 味の素株式会社 リン吸収抑制活性を有するポリアミノ酸化合物及びリン吸収抑制剤
KR102069498B1 (ko) * 2007-09-28 2020-01-23 포톨라 파마슈티컬스, 인코포레이티드 인자 Ｘａ 저해제에 대한 안티도트 및 그것을 사용하는 방법
GB2476643B (en) 2009-12-23 2012-11-14 Haomamedica Ltd 1,4-Dihydro-1,4-dioxonaphtalene derivatives as anticoagulants
TWI513466B (zh) 2010-01-20 2015-12-21 Boehringer Ingelheim Int 抗凝血劑解毒劑
EA201301090A1 (ru) 2011-03-30 2014-05-30 Бёрингер Ингельхайм Интернациональ Гмбх Антидоты антикоагулянтов

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3678157A (en) * 1968-10-23 1972-07-18 Oreal Hair treatment compositions containing polycondensable compounds

Also Published As

Publication number Publication date
UA116336C2 (uk) 2018-03-12
SI2785700T1 (sl) 2016-09-30
CA2856540C (en) 2018-04-03
US20180207152A1 (en) 2018-07-26
CN104080772B (zh) 2016-10-05
US20210169874A1 (en) 2021-06-10
BR112014012892A8 (pt) 2021-06-08
IL232788A0 (en) 2014-08-03
PE20141295A1 (es) 2014-10-01
AR089020A1 (es) 2014-07-23
ME02424B (me) 2016-09-20
CY1117414T1 (el) 2017-04-26
HK1202858A1 (en) 2015-10-09
US20240366592A1 (en) 2024-11-07
HRP20160513T1 (hr) 2016-07-15
EP2785700B1 (en) 2016-03-09
ZA201404793B (en) 2015-04-29
US9522892B2 (en) 2016-12-20
PL2785700T3 (pl) 2016-09-30
SMT201600161B (it) 2016-07-01
CO6990738A2 (es) 2014-07-10
BR112014012892B1 (pt) 2022-12-20
MX349514B (es) 2017-08-02
CR20140310A (es) 2014-08-20
NZ625337A (en) 2016-11-25
DK2785700T3 (en) 2016-06-13
EA201490823A1 (ru) 2015-01-30
EA027603B1 (ru) 2017-08-31
US20170056396A1 (en) 2017-03-02
CA2856540A1 (en) 2013-06-06
JP2014534270A (ja) 2014-12-18
IL232788B (en) 2018-05-31
ECSP14006696A (es) 2015-06-30
ES2569674T3 (es) 2016-05-12
KR20140107259A (ko) 2014-09-04
KR101892330B1 (ko) 2018-08-27
RS54738B1 (sr) 2016-10-31
BR112014012892A2 (pt) 2017-06-13
US20130137702A1 (en) 2013-05-30
JP6134731B2 (ja) 2017-05-24
AP2014007662A0 (en) 2014-05-31
SG11201402713WA (en) 2014-06-27
HUE027452T2 (en) 2016-09-28
AU2012345975A1 (en) 2014-05-29
CL2014001399A1 (es) 2014-11-03
US9877961B2 (en) 2018-01-30
PT2785700E (pt) 2016-06-02
WO2013082210A1 (en) 2013-06-06
PH12014501176A1 (en) 2014-09-01
CN104080772A (zh) 2014-10-01
EP2785700A1 (en) 2014-10-08
PH12014501176B1 (en) 2014-09-01
MX2014006349A (es) 2014-09-04

Similar Documents

Publication Publication Date Title
US20240366592A1 (en) Anticoagulant reversal agents
ES2384116T3 (es) Sales y polimorfos farmacéuticos de N-(5-cloro-2-piridinil)-2-[[4-[(dimetilamino)iminometil]benzoil]amino]-5-metoxi-benzamida, un inhibidor del factor XA
CN1078070C (zh) 苯并噻吩衍生物在制备抑制凝血酶药物中的用途
AU754958B2 (en) Novel urokinase inhibitors
US20130296245A1 (en) Prolinamiade derivatives as thrombin inhibitor, prepraration method and application thereof
CN103420985B (zh) 作为前药的达比加群酯衍生物及其制备方法和用途
OA16905A (en) Anticoagulant reversal agents.
HK1202858B (en) Anticoagulant reversal agents
CN103880797B (zh) 苯并呋喃类化合物及其医药用途
NZ625337B2 (en) Anticoagulant reversal agents
Liu et al. Antithrombotic drug—apixaban
Pauls et al. The design of competitive, small-molecule inhibitors of coagulation factor Xa
CA2230445C (en) Fibrinogen receptor antagonists and medicinal preparations containing the same as the active ingredient
JPS63238051A (ja) フエニルアラニン誘導体および蛋白分解酵素阻害剤
CN105367622A (zh) 一种阿加曲班化合物
Sidhu Designing allosteric inhibitors of thrombin
Hens et al. The Role of Kinetics in High Throughput Screening for Drugs
Pauls¹ et al. The Design of Competitive, Small-molecule Inhibitors of Coagulation
CN104418934A (zh) 抗凝血化合物、其制备方法和用途、及包含其的药物组合物
WO2001040224A1 (en) Diketopiperazine derivatives to inhibit thrombin

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
HB Alteration of name in register

Owner name: PEROSPHERE PHARMACEUTICALS INC.

Free format text: FORMER NAME(S): PEROSPHERE INC.

PC Assignment registered

Owner name: COVIS PHARMA GMBH

Free format text: FORMER OWNER(S): PEROSPHERE PHARMACEUTICALS INC.